A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin

The combination of rosuvastatin 10 mg/ezetimibe 10 mg was an effectively alternative therapy superior to rosuvastatin 20 mg or 10 mg with a greater effect on lowering LDL-C and a lower incidence of drug-related adverse events in Chinese patients.